• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ImmunoCellular, MD Anderson partner on stem cell program

ImmunoCellular, MD Anderson partner on stem cell program

November 13, 2015
CenterWatch Staff

ImmunoCellular Therapeutics has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. Yee is an internationally recognized researcher and leading expert in identifying and isolating cytotoxic T cells. He serves as professor, department of melanoma medical oncology, division of cancer medicine, as well as professor, department of immunology, division of cancer medicine, and director, solid tumor cell therapy, center for cancer immunology research, at MD Anderson.

Yee will focus on identifying T cells that strongly bind and kill tumor cells expressing an undisclosed target antigen. Then the T cell receptors (TCRs) will be sequenced and their corresponding DNA will be placed into stem cells to create preclinical therapeutic candidates for further evaluation. The ultimate goal of the work is to enable a clinical program based on hematopoietic stem cells that are isolated from the patient, engineered in the lab and then returned to the patient to create a population of antigen-specific killer T cells that target and kill the tumor. ImmunoCellular’s Stem-to-T-cell platform technology has the potential to overcome the issue of short-lived T cell responses seen with the present forms of T cell and CAR-T therapies.

“With our lead phase III program ICT-107 underway and financed, we are now focusing additional resources and attention on moving our Stem-to-T-cell program toward clinical development,” said Andrew Gengos, ImmunoCellular chief executive officer. “Our collaboration with Dr. Yee and MD Anderson is an important step in our efforts to build a leading cancer immunotherapy company, and we look forward to potentially establishing more collaborations and bringing additional promising technologies into ImmunoCellular.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing